JILIN, China, Jan. 4 /Xinhua-PRNewswire/ -- Global Pharmatech, Inc. (OTC Bulletin Board: GBLP.OB) a company that develops, manufactures and markets proprietary botanical drugs and dietary supplements, announced that the Chinese State Food and Drug Administration (SFDA), has recently issued a new policy on the preclinical development of new drug products. This policy will force Chinese drug companies to use only GLP ("Good Laboratory Practice")-certified labs to conduct pre-clinical trials. Currently there are only 22 GLP-certified labs located in China and Global Pharmatech owns one of them.

As now required by the SFDA, all pivotal pharmacology and toxicology studies for preclinical development of "new drugs" must be conducted in GLP- certified laboratories. A "new drug" is defined by the SFDA as any chemical, biological and botanical drug product which will be registered to the SFDA as a drug product after January 1, 2007. Preclinical evaluation is a necessary step for the development of all new drugs. Preclinical evaluation of a new drug involves a series of pharmacology and toxicology experiments which can be very costly for a pharmaceutical company. As of the end of November 2006, only twenty-two preclinical facilities had been inspected and recognized as GLP certified laboratories by the SFDA. Jilin Tian Yao Drug Safety Evaluation Co., Ltd. ("JDE"), a 99.5% owned indirect subsidiary of GBLP is one of these laboratories and one of only two privately owned GLP laboratories certified by the Chinese authorities. GBLP owns its interest in JDE through its wholly- owned subsidiary, Natural Pharmatech, Inc.

JDE was established in 2003 and became a GLP certified laboratory through a series of SFDA inspection and evaluation procedures. Currently, JDE has the capacity to perform almost all types of toxicology studies for new drug evaluation, including toxicology studies in rodents or non-rodents, reproductive toxicology studies, mutagenicity studies, carcinogenicity studies, immunotoxicity studies. JDE is also able to conduct safety pharmacology and local irritation studies. During the past few years, JDE has been providing its services to various domestic and international pharmaceutical companies, including its involvement in pivotal toxicology studies for more than thirty new drug products.

Ms. Lianqin Qu, Chairwoman and CEO commented: "We are extremely pleased to see this new policy issued by the SFDA. We believe that it is an important step to bring Chinese regulatory requirements of preclinical development up to international standards. As one of the few GLP-certified labs currently operating in China, we believe that the implementation of this new policy will give us more opportunities to participate in the development of new drug products in China."

About Global Pharmatech

Global Pharmatech, through its subsidiaries, develops, manufactures and markets proprietary drugs that are based on Traditional Chinese Medicine using modern facilities and advanced R&D technologies. The company offers a full range of start-to-finish biotech services, from research and testing to manufacture and sale of liquid and solid dose products. The Company employs unique proprietary extraction methods and also licenses patents and technologies for botanical/biological drug products. Global Pharmatech's operations are currently based in the People's Republic of China with sales distribution centers in China, Malaysia, Singapore and Indonesia. For more information, please visit www.global-pharmatech.com

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to successfully develop and commercialize products, competitive products in our key markets, changes in consumer demand for our products, legislative, regulatory and competitive developments and general economic conditions. Our SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

    For more information, please contact:

     Zhuojun Li
     Investor Relations
     Global Pharmatech, Inc.
     Tel:   +1-
     Email: 

SOURCE Global Pharmatech, Inc.